TY - JOUR
T1 - Neurophysiological biomarkers for Lewy body dementias
AU - Cromarty, Ruth A.
AU - Elder, Greg J.
AU - Graziadio, Sara
AU - Baker, Mark
AU - Bonanni, Laura
AU - Onofrj, Marco
AU - O'Brien, John T.
AU - Taylor, John-Paul
N1 - Copyright © 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
PY - 2016/1
Y1 - 2016/1
N2 - OBJECTIVE: Lewy body dementias (LBD) include both dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), and the differentiation of LBD from other neurodegenerative dementias can be difficult. Currently, there are few biomarkers which might assist early diagnosis, map onto LBD symptom severity, and provide metrics of treatment response. Traditionally, biomarkers in LBD have focussed on neuroimaging modalities; however, as biomarkers need to be simple, inexpensive and non-invasive, neurophysiological approaches might also be useful as LBD biomarkers.METHODS: In this review, we searched PubMED and PsycINFO databases in a semi-systematic manner in order to identify potential neurophysiological biomarkers in the LBDs.RESULTS: We identified 1491 studies; of these, 37 studies specifically examined neurophysiological biomarkers in LBD patients. We found that there was substantial heterogeneity with respect to methodologies and patient cohorts.CONCLUSION: Generally, many of the findings have yet to be replicated, although preliminary findings reinforce the potential utility of approaches such as quantitative electroencephalography and motor cortical stimulation paradigms.SIGNIFICANCE: Various neurophysiological techniques have the potential to be useful biomarkers in the LBDs. We recommend that future studies focus on maximising the diagnostic specificity and sensitivity of the most promising neurophysiological biomarkers.
AB - OBJECTIVE: Lewy body dementias (LBD) include both dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), and the differentiation of LBD from other neurodegenerative dementias can be difficult. Currently, there are few biomarkers which might assist early diagnosis, map onto LBD symptom severity, and provide metrics of treatment response. Traditionally, biomarkers in LBD have focussed on neuroimaging modalities; however, as biomarkers need to be simple, inexpensive and non-invasive, neurophysiological approaches might also be useful as LBD biomarkers.METHODS: In this review, we searched PubMED and PsycINFO databases in a semi-systematic manner in order to identify potential neurophysiological biomarkers in the LBDs.RESULTS: We identified 1491 studies; of these, 37 studies specifically examined neurophysiological biomarkers in LBD patients. We found that there was substantial heterogeneity with respect to methodologies and patient cohorts.CONCLUSION: Generally, many of the findings have yet to be replicated, although preliminary findings reinforce the potential utility of approaches such as quantitative electroencephalography and motor cortical stimulation paradigms.SIGNIFICANCE: Various neurophysiological techniques have the potential to be useful biomarkers in the LBDs. We recommend that future studies focus on maximising the diagnostic specificity and sensitivity of the most promising neurophysiological biomarkers.
KW - Electroencephalography/methods
KW - Humans
KW - Lewy Body Disease/diagnosis
KW - Magnetoencephalography/methods
KW - Neuropsychological Tests
KW - Transcranial Magnetic Stimulation/methods
U2 - 10.1016/j.clinph.2015.06.020
DO - 10.1016/j.clinph.2015.06.020
M3 - Review article
C2 - 26183755
SN - 1388-2457
VL - 127
SP - 349
EP - 359
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
IS - 1
ER -